ArticleAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2022

Evolocumab's Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER.

Folkert H van Bruggen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.